RT Journal Article
T1 Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository.
A1 Efthymiou, Maria
A1 Mackie, Ian J
A1 Lane, Philip J
A1 Andrade, Danieli
A1 Willis, Rohan
A1 Erkan, Doruk
A1 Sciascia, Savino
A1 Krillis, Steven
A1 Bison, Elisa
A1 Borges Galhardo Vendramini, Margarete
A1 Romay-Penabad, Zurina
A1 Qi, Miao
A1 Tektonidou, Maria
A1 Ugarte, Amaia
A1 Chighizola, Cecilia
A1 Belmont, H Michael
A1 Aguirre, Maria Angeles
A1 Ji, Lanlan
A1 Branch, D Ware
A1 de Jesus, Guilherme
A1 Fortin, Paul R
A1 Andreoli, Laura
A1 Petri, Michelle
A1 Cervera, Ricard
A1 Rodriguez, Esther
A1 Knight, Jason S
A1 Atsumi, Tatsuya
A1 Vega, Joann
A1 Sevim, Ecem
A1 Bertolaccini, Maria Laura
A1 Pengo, Vittorio
A1 Cohen, Hannah
K1 Russell's viper venom time
K1 Antiphospholipid antibodies
K1 Antiphospholipid syndrome
K1 Lupus anticoagulant
K1 Thrombosis
AB Variability remains a challenge in lupus anticoagulant (LA) testing. To validate LA test performance between Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core laboratories and examine agreement in LA status between Core and local/hospital laboratories contributing patients to this prospective registry. Five Core laboratories used the same reagents, analyzer type, protocols, and characterized samples for LA validation. Non-anticoagulated registry samples were retested at the corresponding regional Core laboratories and anticoagulated samples at a single Core laboratory. Categorical agreement and discrepancies in LA status between Core and local/hospital laboratories were analyzed. Clotting times for the reference/characterized plasmas used for normalized ratios were similar between Core laboratories (CV  Laboratories can achieve good agreement in LA performance by use of the same reagents, analyzer type, and protocols. The standardized Core laboratory results underpin accurate interpretation of APS ACTION clinical data.
PB Elsevier
YR 2019
FD 2019-07-25
LK http://hdl.handle.net/10668/14344
UL http://hdl.handle.net/10668/14344
LA en
NO Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, et al. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. J Thromb Haemost. 2019 Dec;17(12):2069-2080
NO We would like to thank NIBSC, South Mimms, UK for kindly providing the 1st International Reference Panel for LA plasma; Werfen for providing the ACL TOP500 analyzer and LA reagents; and Diagnostic Reagents Ltd for providing Taipan and Ecarin venoms; without having any input in the study and/or analysis of the data or results. Data management was performed using REDCAP provided by the Clinical and Translational Science Center at Weill Cornell Medicine (CTSC grant UL1 TR000457)
DS RISalud
RD Apr 7, 2025